Cellectar Biosciences, Inc. Q3 2026 Earnings Call Summary
Cellectar (CLRB) Q3 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences Q3 2026 Earnings Call Transcript
Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.